Legal & General Group
BCAX

Legal & General Group’s Bicara Therapeutics BCAX Stock Holding History

Legal & General Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$442K Buy
22,227
+6,269
+39% +$108K ﹤0.01% 2391
2025
Q4 		$269K Buy
15,958
+12,802
+406% +$219K ﹤0.01% 2548
2025
Q3 		$49.8K Hold
3,156
– – ﹤0.01% 2731
2025
Q2 		$29.3K Buy
3,156
+1,233
+64% +$14.7K ﹤0.01% 2862
2025
Q1 		$25.1K Hold
1,923
– – ﹤0.01% 2869
2024
Q4 		$33.4K Buy
+1,923
New +$40K ﹤0.01% 2859

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Legal & General Group's BCAX Position: Q1 2026 in Review

Legal & General Group increased its Bicara Therapeutics (BCAX) stake by 39% in Q1 2026, buying an estimated $108K and bringing the position to 22,227 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #2391.

Legal & General Group first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Legal & General Group held 22,227 shares of Bicara Therapeutics worth $442K as of Q1 2026.
  • Legal & General Group bought 6,269 Bicara Therapeutics shares in Q1 2026, an estimated $108K.
  • Bicara Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2391 holding.
  • Legal & General Group first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.